NYSE
MRK

Merck & Company Inc

Drug Manufacturers-General
Healthcare

Prices are adjusted according to historical splits.

Merck & Company Inc Stock Price

Vitals

Today's Low:
$107.555
Today's High:
$109.48
Open Price:
$108.42
52W Low:
$82.8306
52W High:
$118.8559
Prev. Close:
$108.6
Volume:
4605315

Company Statistics

Market Cap.:
$275.57 billion
Book Value:
15.237
Revenue TTM:
$58.31 billion
Operating Margin TTM:
14.87%
Gross Profit TTM:
$42.08 billion
Profit Margin:
5.34%
Return on Assets TTM:
5.12%
Return on Equity TTM:
7.61%

Company Profile

Merck & Company Inc had its IPO on 1978-01-13 under the ticker symbol MRK.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Merck & Company Inc has a staff strength of 67,000 employees.

Stock update

Shares of Merck & Company Inc opened at $108.42 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $107.56 - $109.48, and closed at $109.02.

This is a +0.39% increase from the previous day's closing price.

A total volume of 4,605,315 shares were traded at the close of the day’s session.

In the last one week, shares of Merck & Company Inc have slipped by -0.75%.

Merck & Company Inc's Key Ratios

Merck & Company Inc has a market cap of $275.57 billion, indicating a price to book ratio of 6.3616 and a price to sales ratio of 4.7132.

In the last 12-months Merck & Company Inc’s revenue was $58.31 billion with a gross profit of $42.08 billion and an EBITDA of $12.33 billion. The EBITDA ratio measures Merck & Company Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Merck & Company Inc’s operating margin was 14.87% while its return on assets stood at 5.12% with a return of equity of 7.61%.

In Q2, Merck & Company Inc’s quarterly earnings growth was a negative -34.7% while revenue growth was a positive 3%.

Merck & Company Inc’s PE and PEG Ratio

Forward PE
14.7493
Trailing PE
89.0164
PEG
1.359

Its diluted EPS in the last 12-months stands at $1.22 per share while it has a forward price to earnings multiple of 14.7493 and a PEG multiple of 1.359. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Merck & Company Inc’s profitability.

Merck & Company Inc stock is trading at a EV to sales ratio of 5.1208 and a EV to EBITDA ratio of 13.9631. Its price to sales ratio in the trailing 12-months stood at 4.7132.

Merck & Company Inc stock pays annual dividends of $2.84 per share, indicating a yield of 2.69% and a payout ratio of 103.91%.

Balance sheet and cash flow metrics

Total Assets
$104.47 billion
Total Liabilities
$23.39 billion
Operating Cash Flow
$-11443000000.00
Capital Expenditure
$965 million
Dividend Payout Ratio
103.91%

Merck & Company Inc ended 2024 with $104.47 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $104.47 billion while shareholder equity stood at $38.69 billion.

Merck & Company Inc ended 2024 with $996.00 million in deferred long-term liabilities, $23.39 billion in other current liabilities, 1788000000.00 in common stock, $54.20 billion in retained earnings and $21.20 billion in goodwill. Its cash balance stood at $5.66 billion and cash and short-term investments were $6.38 billion. The company’s total short-term debt was $2,839,000,000 while long-term debt stood at $34.07 billion.

Merck & Company Inc’s total current assets stands at $29.98 billion while long-term investments were $1.21 billion and short-term investments were $718.00 million. Its net receivables were $11.03 billion compared to accounts payable of $3.44 billion and inventory worth $5.93 billion.

In 2024, Merck & Company Inc's operating cash flow was $-11443000000.00 while its capital expenditure stood at $965 million.

Comparatively, Merck & Company Inc paid $1.04 in dividends in 2024.

Other key metrics

Current Trading Price
$109.02
52-Week High
$118.8559
52-Week Low
$82.8306
Analyst Target Price
$124.32

Merck & Company Inc stock is currently trading at $109.02 per share. It touched a 52-week high of $118.8559 and a 52-week low of $118.8559. Analysts tracking the stock have a 12-month average target price of $124.32.

Its 50-day moving average was $108.17 and 200-day moving average was $109.17 The short ratio stood at 1.92 indicating a short percent outstanding of 0%.

Around 8.9% of the company’s stock are held by insiders while 7764.9% are held by institutions.

Frequently Asked Questions About Merck & Company Inc

The stock symbol (also called stock or share ticker) of Merck & Company Inc is MRK

The IPO of Merck & Company Inc took place on 1978-01-13

Similar Industry Stocks (Drug Manufacturers-General)

Last Price
Chg
Chg%
$90.2
0.47
+0.52%
$26.85
0.14
+0.52%
$26.97
0.19
+0.71%
$0.15
-0.01
-4.84%
$1104.05
-3.5
-0.32%
$31.28
-1.9
-5.73%
$75.05
1.18
+1.6%
$81.45
-4.7
-5.46%
$1.71
-0.06
-3.39%
$2345.95
-51.7
-2.16%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Address

2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033